not tagged
not tagged
[]
evolut trial: tavr is noninferior to savr for low risk patients in terms of mortality and disabling stroke at 24 months. more a.fib (new) and major bleeding in savr arm. more pvl and need of ppm in tavr arm. #acc23 #neworleansla
Cardiology fellow | Chief resident | Learner | Teacher | Painter |#MedTwitter #CardioTwitter 🫀